Stockscreener 앱 받기
2.20
7.32%
0.15
시간 외 거래:
2.20
Beyondspring Inc 주식(BYSI)의 최신 뉴스
Acadian Asset Management LLC Has $34,000 Stock Position in BeyondSpring Inc. (NASDAQ:BYSI) - Defense World
BeyondSpring reports promising phase 2 NSCLC study results - Investing.com
BeyondSpring plinabulin, Merck Keytruda combo shows promise in NSCLC - MSN
BeyondSpring reports promising phase 2 NSCLC study results - Investing.com India
BeyondSpring reports safer NSCLC therapy option - Investing.com India
BeyondSpring reports safer NSCLC therapy option - Investing.com
BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024 - StockTitan
BeyondSpring Presents Efficacy/Safety Results from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at ESMO Congress 2024 - StockTitan
BeyondSpring presented interim Phase 2 data on 303 Study - TipRanks
BeyondSpring Presents Efficacy/Safety Results from a Phase - GlobeNewswire
BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase - GlobeNewswire
BeyondSpring (NASDAQ:BYSI) Trading Up 3.3% - MarketBeat
BeyondSpring Delivers Oral Presentation at ISLAC 2024 World Conference on Lung Cancer of its Lead Anti-Cancer Asset Plinabulin Showcasing Positive Final Phase 3 Data in 2L/3L NSCLC EGFR Wild-Type... - Markets Insider
BeyondSpring announces Dublin-3 final phase 3 efficacy data - TipRanks
BeyondSpring Delivers Oral Presentation at ISLAC 2024 World Conference on Lung Cancer of its Lead Anti-Cancer Asset Plinabulin Showcasing Positive Final Phase 3 Data in 2L/3L NSCLC EGFR Wild-Type with Concurrent Publication in the Lancet Respira - GlobeNewswire
BeyondSpring Delivers Oral Presentation at ISLAC 2024 World Conference on Lung Cancer of its Lead Anti-Cancer Asset Plinabulin Showcasing Positive Final Phase 3 Data in 2L/3L NSCLC EGFR Wild-Type with Concurrent Publication in the Lancet Respira - Yahoo Finance
BeyondSpring Delivers Oral Presentation at ISLAC 2024 World Conference on Lung Cancer of its Lead Anti-Cancer Asset Plinabulin Showcasing Positive Final Phase 3 Data in 2L/3L NSCLC EGFR Wild-Type with Concurrent Publication in the Lancet Respira - StockTitan
BeyondSpring Announces Oral Presentation at the 2024 World - GlobeNewswire
BeyondSpring Announces Oral Presentation at the 2024 World Conference on Lung Cancer and Two Poster Presentations During ESMO Congress 2024 Showcasing its Lead Anti-Cancer Asset, Plinabulin - StockTitan
Is BeyondSpring (NASDAQ:BYSI) In A Good Position To Invest In Growth? - Yahoo Finance
BeyondSpring Inc. Reports Mid-Year Financials - TipRanks
Global Chemotherapy Drugs Market to Grow Substantially at a CAGR of ~9% by 2030 | DelveInsight - The Malaysian Reserve
Global Chemotherapy Drugs Market to Grow Substantially at a CAGR of ~9% by 2030 | DelveInsight - PR Newswire UK
BeyondSpring (NASDAQ:BYSI) Stock Price Down 0.5% - MarketBeat
BYSI (BeyondSpring) EV-to-Revenue : 40.75 (As of Aug. 19, 2024) - GuruFocus.com
BYSI (BeyondSpring) GF Value Rank : 10 (As of Aug. 18, 2024) - GuruFocus.com
BYSI (BeyondSpring) 3-Year Dividend Growth Rate : 0.00% (As of Dec. 2023) - GuruFocus.com
BioWorld Cancer Index drops overall; Blueprint, TG catapulted in Q1 - BioWorld Online
Chemotherapy Induced Neutropenia Market Forecasted to Surge - openPR
SEED Therapeutics (SEED) Enters into Strategic Research - GlobeNewswire
SEED Therapeutics (SEED) Enters into Strategic Research Collaboration with Eisai Co., Ltd. to Discover and Develop Novel Molecular Glue Degraders for Neurodegeneration and Oncology Indications - StockTitan
SEED Therapeutics (SEED) Enters into Strategic Research Collaboration with Eisai Co., Ltd. to Discover and Develop Novel Molecular Glue Degraders for Neurodegeneration and Oncology Indications - GlobeNewswire
Global Cancer Supportive Care Drugs Market to Cross 17 Billion Mark by 2030| DelveInsight - 新浪香港
Global Cancer Supportive Care Drugs Market to Cross 17 Billion Mark by 2030| DelveInsight - India Shorts
Drugs for Traveler’s Diarrhea Industry to Witness an Outstanding Growth by 2030 |GSK, Salix Pharmaceuticals, Chiesi Farm – Moose Gazette - Moose Gazette
O Shaughnessy Asset Management LLC Buys 21,202 Shares of Haleon plc (NYSE:HLN) - Defense World
Cencora (NYSE:COR) Releases FY 2024 Earnings Guidance - Defense World
Public Employees Retirement Association of Colorado Sells 1,333 Shares of WestRock (NYSE:WRK) - Defense World
Leatt (OTCMKTS:LEAT) Stock Passes Above 50 Day Moving Average of $6.76 - Defense World
Schwarz Dygos Wheeler Investment Advisors LLC Sells 5,532 Shares of Apple Inc. (NASDAQ:AAPL) - Defense World
Apple Inc. (NASDAQ:AAPL) Shares Acquired by Westchester Capital Management Inc. - Defense World
Rehmann Capital Advisory Group Sells 743 Shares of Apple Inc. (NASDAQ:AAPL) - Defense World
SG Americas Securities LLC Invests $69,000 in Lithium Americas Corp. (NYSE:LAC) - Defense World
Vital Energy (VTLE) Set to Announce Quarterly Earnings on Wednesday - Defense World
UBS ETRACS 2xLeveraged Long Wells Fargo Business Development Company Index ETN (NYSEARCA:BDCL) Stock Price Crosses Below Two Hundred Day Moving Average of $2.44 - Defense World
OneSoft Solutions (OTCMKTS:OSSIF) Stock Price Passes Below 200 Day Moving Average of $0.57 - Defense World
Caspase 3 Market – 37% of Growth to Originate from APAC -Aptose Biosciences Inc, BeyondSpring Pharmaceuticals Inc, Conat – Moose Gazette - Moose Gazette
Acadian Asset Management LLC Trims Position in Natural Health Trends Corp. (NASDAQ:NHTC) - Defense World
Acadian Asset Management LLC Decreases Stock Position in Emergent BioSolutions Inc. (NYSE:EBS) - Defense World
Chemotherapy Induced Anemia Drug Industry Growth Factors, Applications, and Forecast by (2024-2035) - La Funcion mx
Caspase 8 Market Analysis, Trends, Growth, Research And Forecast 2030 - Moose Gazette
Top 5 NASDAQ Pharma Stocks of 2024 - Investing News Network
BeyondSpring (NASDAQ:BYSI) Trading Up 3.1% - MarketBeat
Molecular Glues Clinical Trial Pipeline Appears Robust With 10+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Malaysian Reserve
Molecular Glues Clinical Trial Pipeline Appears Robust With 10+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - PR Newswire UK
Caspase 3 Market Size | Global Demand and Business Trends 2032 - WICZ
BeyondSpring Inc (BYSI)'s highs and lows: A closer look at its stock price fluctuations – US Post News - US Post News
BeyondSpring (NASDAQ:BYSI) Shares Down 8.8% - MarketBeat
Palatin Technologies, Inc. (PTN) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Movies UK
Results from BeyondSpring Inc (BYSI) show potential - US Post News
BeyondSpring Inc. Announces Share IssuanceTipRanks.com - TipRanks
BeyondSpring (BYSI) Looks Good: Stock Adds 5.1% in Session - Yahoo New Zealand News
Codexis (CDXS) Surges 9.7%: Is This an Indication of Further Gains? - Yahoo Lifestyle Singapore
Market Insights: BeyondSpring Inc (BYSI)'s Notable Drop of -1.81, Closing at 2.71 – DWinneX - The Dwinnex
0.87%
자본화:
|
볼륨(24시간):